Anzeige
Mehr »
Login
Mittwoch, 22.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Kursexplosion von 383 % seit November und massiver Solana-Outperformer!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PRLN | ISIN: US85205L1070 | Ticker-Symbol:
NASDAQ
22.01.25
17:39 Uhr
34,940 US-Dollar
-1,390
-3,83 %
1-Jahres-Chart
SPRINGWORKS THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
SPRINGWORKS THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur SPRINGWORKS THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
14.01.SWTX Announces 2024 Preliminary Results, 2025 Goals, Stock Down6
13.01.SpringWorks Therapeutics Stock Sees RS Rating Jump To 861
13.01.BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps.10
13.01.SpringWorks to Develop Rappta's First-in-Class Cancer Drug 3
SPRINGWORKS THERAPEUTICS Aktie jetzt für 0€ handeln
13.01.SpringWorks Therapeutics dips 10%, gives prelim Q4 and FY topline estimates8
13.01.Rappta Therapeutics enters into a global license agreement with SpringWorks Therapeutics for a pre-clinical first-in-class molecular glue targeting PP2A182Goal to accelerate development and commercialization of the lead asset RPT04402 for the treatment of a subset of uterine cancersFinancials include a $13 million upfront payment and potential...
► Artikel lesen
13.01.SpringWorks Therapeutics, Inc. - 8-K, Current Report4
10.01.SpringWorks Therapeutics jumps amid takeover speculation2
08.01.Guggenheim Cuts SpringWorks Therapeutics (NASDAQ:SWTX) Price Target to $78.002
08.01.SpringWorks Therapeutics Stock Gets A RS Rating Lift1
20.11.24SpringWorks started at outperform by Evercore ahead of FDA decision9
13.11.24SpringWorks' Q3 Loss Narrower Than Expected, Revenues Miss Mark4
12.11.24SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights227- Achieved $49.3 million in OGSIVEO® (nirogacestat) net product revenue in the third quarter - - Long-term follow-up data from the Phase 3 DeFi trial of nirogacestat in adults with desmoid tumors...
► Artikel lesen
11.11.24SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Announces Publication of the Pivotal Phase 2b ReNeu Trial Evaluating Mirdametinib in Adults and Children with NF1-PN in the Journal of Clinical ...114- Mirdametinib treatment demonstrated significant confirmed objective response rates and a manageable safety profile in adults and children with NF1-PN - - Patients achieved deep and durable reductions...
► Artikel lesen
07.11.24SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Announces Long-Term Efficacy and Safety Data from Phase 3 DeFi Trial of OGSIVEO (nirogacestat) in Adults with Desmoid Tumors to be Presented at ...103- Long-term follow-up data highlight further reductions in tumor size, increase in ORR with additional CRs, sustained improvement in desmoid tumor symptoms, and consistent safety profile, now with...
► Artikel lesen
22.10.24SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 20241
04.09.24SpringWorks Therapeutics CEO sells over $1.9m in company stock3
04.09.24JPMorgan raises SpringWorks stock price target, maintains overweight rating33
29.08.24SWTX's NDA for Rare Tumor Drug Gets Priority Review From FDA1
29.08.24SpringWorks shares hold buy rating as FDA accepts drug application2
Seite:  Weiter >>
39 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2